These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

257 related articles for article (PubMed ID: 33611059)

  • 1. Serum levels of soluble programmed death-ligand 1 (sPD-L1): A possible biomarker in predicting post-treatment outcomes in patients with early hepatocellular carcinoma.
    Mocan T; Ilies M; Nenu I; Craciun R; Horhat A; Susa R; Minciuna I; Rusu I; Mocan LP; Seicean A; Iuga CA; Hajjar NA; Sparchez M; Leucuta DC; Sparchez Z
    Int Immunopharmacol; 2021 May; 94():107467. PubMed ID: 33611059
    [TBL] [Abstract][Full Text] [Related]  

  • 2. High levels of the soluble programmed death-ligand (sPD-L1) identify hepatocellular carcinoma patients with a poor prognosis.
    Finkelmeier F; Canli Ö; Tal A; Pleli T; Trojan J; Schmidt M; Kronenberger B; Zeuzem S; Piiper A; Greten FR; Waidmann O
    Eur J Cancer; 2016 May; 59():152-159. PubMed ID: 27039170
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Study of Serum Soluble Programmed Death Ligand 1 as a Prognostic Factor in Hepatocellular Carcinoma in Egyptian Patients.
    El-Gebaly F; Abou-Saif S; Elkadeem M; Helmy A; Abd-Elsalam S; Yousef M; Elkhouly RA; Amer IF; El-Demerdash T
    Curr Cancer Drug Targets; 2019; 19(11):896-905. PubMed ID: 31538897
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The correlation and prognostic value of serum levels of soluble programmed death protein 1 (sPD-1) and soluble programmed death-ligand 1 (sPD-L1) in patients with hepatocellular carcinoma.
    Chang B; Huang T; Wei H; Shen L; Zhu D; He W; Chen Q; Zhang H; Li Y; Huang R; Li W; Wu P
    Cancer Immunol Immunother; 2019 Mar; 68(3):353-363. PubMed ID: 30506460
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Pre-treatment serum levels of soluble programmed cell death-ligand 1 predict prognosis in patients with hepatitis B-related hepatocellular carcinoma.
    Han X; Gu YK; Li SL; Chen H; Chen MS; Cai QQ; Deng HX; Zuo MX; Huang JH
    J Cancer Res Clin Oncol; 2019 Feb; 145(2):303-312. PubMed ID: 30267213
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Prognostic value of programmed cell death ligand 1 (PD-L1) for hepatocellular carcinoma: a meta-analysis.
    Li XS; Li JW; Li H; Jiang T
    Biosci Rep; 2020 Apr; 40(4):. PubMed ID: 32255189
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Clinical significance of soluble programmed cell death ligand-1 (sPD-L1) in hepatocellular carcinoma patients treated with radiotherapy.
    Kim HJ; Park S; Kim KJ; Seong J
    Radiother Oncol; 2018 Oct; 129(1):130-135. PubMed ID: 29366520
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Establishing peripheral PD-L1 as a prognostic marker in hepatocellular carcinoma patients: how long will it come true?
    Sun DW; An L; Huang HY; Sun XD; Lv GY
    Clin Transl Oncol; 2021 Jan; 23(1):82-91. PubMed ID: 32462395
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Prognostic value of soluble programmed cell death-1 (sPD-1) and soluble programmed cell death ligand-1 (sPD-L1) for hepatocellular carcinoma: a systematic review and meta-analysis.
    Xue JS; Liu H; Meng GX; Ding ZN; Yan LJ; Yao SY; Li HC; Dong ZR; Chen ZQ; Hong JG; Li T
    Cancer Immunol Immunother; 2022 Jul; 71(7):1633-1644. PubMed ID: 34750662
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Overexpression of PD-L1 and PD-L2 Is Associated with Poor Prognosis in Patients with Hepatocellular Carcinoma.
    Jung HI; Jeong D; Ji S; Ahn TS; Bae SH; Chin S; Chung JC; Kim HC; Lee MS; Baek MJ
    Cancer Res Treat; 2017 Jan; 49(1):246-254. PubMed ID: 27456947
    [TBL] [Abstract][Full Text] [Related]  

  • 11. High post-treatment serum levels of soluble programmed cell death ligand 1 predict early relapse and poor prognosis in extranodal NK/T cell lymphoma patients.
    Wang H; Wang L; Liu WJ; Xia ZJ; Huang HQ; Jiang WQ; Li ZM; Lu Y
    Oncotarget; 2016 May; 7(22):33035-45. PubMed ID: 27105512
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Circulating levels of PD-L1 and Galectin-9 are associated with patient survival in surgically treated Hepatocellular Carcinoma independent of their intra-tumoral expression levels.
    Sideras K; de Man RA; Harrington SM; Polak WG; Zhou G; Schutz HM; Pedroza-Gonzalez A; Biermann K; Mancham S; Hansen BE; Bart Takkenberg R; van Vuuren AJ; Pan Q; Ijzermans JNM; Sleijfer S; Sprengers D; Dong H; Kwekkeboom J; Bruno MJ
    Sci Rep; 2019 Jul; 9(1):10677. PubMed ID: 31337865
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Soluble PD-L1 Expression in Circulation as a Predictive Marker for Recurrence and Prognosis in Gastric Cancer: Direct Comparison of the Clinical Burden Between Tissue and Serum PD-L1 Expression.
    Shigemori T; Toiyama Y; Okugawa Y; Yamamoto A; Yin C; Narumi A; Ichikawa T; Ide S; Shimura T; Fujikawa H; Yasuda H; Hiro J; Yoshiyama S; Ohi M; Araki T; Kusunoki M
    Ann Surg Oncol; 2019 Mar; 26(3):876-883. PubMed ID: 30565045
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Prognostic impacts of tumoral expression and serum levels of PD-L1 and CTLA-4 in colorectal cancer patients.
    Omura Y; Toiyama Y; Okugawa Y; Yin C; Shigemori T; Kusunoki K; Kusunoki Y; Ide S; Shimura T; Fujikawa H; Yasuda H; Hiro J; Ohi M; Kusunoki M
    Cancer Immunol Immunother; 2020 Dec; 69(12):2533-2546. PubMed ID: 32577816
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Impact of Immune Response on Outcomes in Hepatocellular Carcinoma: Association With Vascular Formation.
    Itoh S; Yoshizumi T; Yugawa K; Imai D; Yoshiya S; Takeishi K; Toshima T; Harada N; Ikegami T; Soejima Y; Kohashi K; Oda Y; Mori M
    Hepatology; 2020 Dec; 72(6):1987-1999. PubMed ID: 32112577
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Soluble PD-L1 as a predictive biomarker in lung cancer: a systematic review and meta-analysis.
    Cheng Y; Wang C; Wang Y; Dai L
    Future Oncol; 2022 Jan; 18(2):261-273. PubMed ID: 34874185
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Elevated soluble programmed death-ligand 1 levels indicate immunosuppression and poor prognosis in hepatocellular carcinoma patients undergoing transcatheter arterial chemoembolization.
    Ma XL; Qu XD; Yang WJ; Wang BL; Shen MN; Zhou Y; Zhang CY; Sun YF; Chen JW; Hu B; Gong ZJ; Zhang X; Pan BS; Zhou J; Fan J; Yang XR; Guo W
    Clin Chim Acta; 2020 Dec; 511():67-74. PubMed ID: 32979338
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Soluble Programmed Cell Death Ligand 1 as a Novel Biomarker for Nivolumab Therapy for Non-Small-cell Lung Cancer.
    Okuma Y; Wakui H; Utsumi H; Sagawa Y; Hosomi Y; Kuwano K; Homma S
    Clin Lung Cancer; 2018 Sep; 19(5):410-417.e1. PubMed ID: 29859759
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Absence of association between pretransplant serum soluble programmed death protein-1 level and prognosis following living donor liver transplantation in patients with hepatocellular carcinoma.
    Na BG; Kim YK; Hwang S; Lee KJ; Park GC; Ahn CS; Kim KH; Moon DB; Ha TY; Song GW; Jung DH; Yang H; Yoon YI; Tak E; Park YH; Lee SG
    Medicine (Baltimore); 2021 Apr; 100(17):e25640. PubMed ID: 33907121
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Increase of Soluble Programmed Cell Death Ligand 1 in Patients with Chronic Hepatitis C.
    Yamagiwa S; Ishikawa T; Waguri N; Sugitani S; Kamimura K; Tsuchiya A; Takamura M; Kawai H; Terai S
    Int J Med Sci; 2017; 14(5):403-411. PubMed ID: 28539815
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 13.